Cardax (Cardax) Float Percentage Of Total Shares Outstanding : 66.26% (As of May. 17, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Cardax Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cardax's float shares is 0.53 Mil. Cardax's total shares outstanding is 0.80 Mil. Cardax's float percentage of total shares outstanding is 66.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cardax's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cardax's Institutional Ownership is 0.00%.

Cardax Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cardax's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.53	/	0.80
	=	66.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardax (Cardax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

IMUN BOM:506365 PPCB HSTC XCNQ:NSHS RSPI BOM:542910 BOM:539206 RBSH GNBT

Traded in Other Exchanges

N/A

Address

2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822

Website

http://www.cardaxpharma.com

Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.

Executives

Paulson Capital Corp	10 percent owner	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc.	10 percent owner	5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc	10 percent owner	811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204